Page 2 - Sage Therapeutics Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sage Therapeutics (NASDAQ:SAGE) Raised to Hold at Baird R W

Baird R W upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other analysts have also weighed in on the company. Wedbush reaffirmed a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics […]

United statesGoldman sachs groupFirst advisors incCanaccord genuity groupLazard asset managementVirtu financialQuest partnersSage therapeutics company profileSage therapeutics incChina universal asset management coMorgan stanleySage therapeuticsFree reportGenuity groupTherapeutics stock downGet free report

Sage Therapeutics (NASDAQ:SAGE) Shares Down 4 2%

Sage Therapeutics (NASDAQ:SAGE) Shares Down 4 2%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Zurcher kantonalbank zurich cantonalbankChina universal asset management coQuest partnersSage therapeutics incGoldman sachs groupFirst advisors incSage therapeuticsGet free reportTruist financialTherapeutics stock downUniversal asset managementKantonalbank zurich cantonalbankFirst advisorsHandelsbanken fonderSage therapeutics daily

Sage Therapeutics (NASDAQ:SAGE) Trading Down 4 2%

Sage Therapeutics (NASDAQ:SAGE) Trading Down 4 2%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Zurcher kantonalbank zurich cantonalbankFirst advisors incSage therapeutics company profileSage therapeutics incJpmorgan chase coChina universal asset management coNeedham companyQuest partnersSage therapeuticsGet free reportUniversal asset managementKantonalbank zurich cantonalbankFirst advisorsHandelsbanken fonderSage therapeutics daily

Sage Therapeutics (NASDAQ:SAGE) Given New $28 00 Price Target at JPMorgan Chase & Co

Sage Therapeutics (NASDAQ:SAGE) Given New $28 00 Price Target at JPMorgan Chase & Co
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandPrimecap management coAlgert globalWellington management groupVanguard group incJpmorgan chase coSage therapeutics incRafferty asset managementNeedham companyGoldman sachs groupRoyal bankMorgan stanleySage therapeutics company profileSage therapeuticsFree report

Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $28 00 by Analysts at JPMorgan Chase & Co

Sage Therapeutics (NASDAQ:SAGE – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $29.00 to $28.00 in a report published on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the stock. […]

Zurcher kantonalbank zurich cantonalbankGoldman sachs groupFirst advisors incSage therapeutics incNeedham companyJpmorgan chase coChina universal asset management coQuest partnersSage therapeuticsFree reportTherapeutics stock downGet free reportUniversal asset managementKantonalbank zurich cantonalbankFirst advisorsSage therapeutics daily